KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Preferred Shares (2017 - 2021)

Arbutus Biopharma (ABUS) has disclosed Preferred Shares for 5 consecutive years, with $161.0 million as the latest value for Q3 2021.

  • Quarterly Preferred Shares rose 10.04% to $161.0 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $161.0 million through Sep 2021, up 10.04% year-over-year, with the annual reading at $149.4 million for FY2020, 8.83% up from the prior year.
  • Preferred Shares hit $161.0 million in Q3 2021 for Arbutus Biopharma, up from $155.9 million in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $161.0 million in Q3 2021 to a low of $49.8 million in Q4 2017.
  • Historically, Preferred Shares has averaged $132.5 million across 5 years, with a median of $135.8 million in 2019.
  • Biggest five-year swings in Preferred Shares: soared 153.39% in 2018 and later grew 8.81% in 2021.
  • Year by year, Preferred Shares stood at $49.8 million in 2017, then skyrocketed by 153.39% to $126.1 million in 2018, then grew by 8.84% to $137.3 million in 2019, then grew by 8.83% to $149.4 million in 2020, then increased by 7.74% to $161.0 million in 2021.
  • Business Quant data shows Preferred Shares for ABUS at $161.0 million in Q3 2021, $155.9 million in Q2 2021, and $152.6 million in Q1 2021.